Marc Diamond, M.D.

Founding Director, Center for Alzheimer's and Neurodegenerative Diseases
Professor of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center

Marc Diamond, M.D., is the founding Director of the Center for Alzheimer’s and Neurodegenerative Diseases, and is a Professor of Neurology and Neurotherapeutics. Dr. Diamond completed an internship, residency, and chief residency in neurology at the University of California, San Francisco (UCSF) in 1997. After a postdoctoral fellowship, he was a faculty member in the Neurology Department at UCSF from 2002-2009. From 2009-2014 he was the David Clayson Professor of Neurology at Washington University in St. Louis, before he was recruited to UT Southwestern. His research focuses on molecular mechanisms of neurodegeneration in Alzheimer’s disease and related disorders, with the goal of developing novel therapies and diagnostic tools. A therapeutic antibody he co-developed at Washington University in St. Louis is now entering clinical trials for treatment of dementia. The Center for Alzheimer’s and Neurodegenerative Diseases is comprised of a multidisciplinary group of investigators who are focused on understanding the basis of progressive protein aggregation in human disease. They are using this knowledge to hasten the day when neurodegeneration can be detected presymptomatically and stopped before it causes disability.

Funded Research

Project Description Researchers Funding
Genetic Targets to Block Tau Propagation: Test Knockdown of Heparan Sulfate Proteoglycan Genes In Vivo

Trans-cellular propagation of tau pathology has been implicated in the progression of Alzheimer’s disease and other tauopathies. We previously have determined the mechanism by which tau aggregates bind the cell surface to trigger uptake via macropinocytosis. This involves direct binding of tau to heparan sulfate proteoglycans (HSPGs) on the cell surface. HSPGs are glycolipid-anchored and transmembrane core proteins that are extensively glycosylated and sulfated by a defined set of cellular enzymes.

2015 to 2017

$300,000

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.
Kiran Yanamandra, Hong Jiang, Thomas E. Mahan, Susan E. Maloney, David F. Wozniak, Marc I. Diamond and David M. Holtzman, Anti-tau antibody reduces insoluble tau and decreases brain atrophy, Annals of Clinical and Translational Neurology, 2(3), March 2015, 278–288